Its been struggling, for sure, but this might be the tailwind it needs to make it attractive again, especially with up to 6 million lapsed members that have expressed willingness to pay to lose weight and who could be brough back in by marketing campaigns like this below (combined with the general social media reflexivity noted above with GLP-1 drugs): Dating Sites & Apps Its perhaps uncomfortable to confront but with nearly a third of every single person in the U.S
A patient can finish a course of GLP-1 treatment significantly lighter and simultaneously in a weaker metabolic position than when they started if muscle preservation was not part of the plan. This is the mechanism behind what clinicians commonly observe in weight cycling
Also referred to as oral semaglutide drops or semaglutide sublingual, companies market these products as a convenient, needle-free way to achieve the same results as injectable GLP-1 medications
Speaking to Your GP About GLP-1 Treatment Options Discussing GLP-1 medications with your GP requires preparation and understanding of NHS prescribing criteria

glucagon-like peptide-1 receptor agonists (GLP-1 RAs) ( 1) 1 GLP-1 RAs 1 GLP-1 RAs 2 GLP-1 Receptor GLP-1 Receptor (GLP-1R) (pleiotropic effects) GLP-1 RAs GLP-1R GLP-1R : GLP-1R (-cells) GLP-1 (glucose-dependent insulinotropic action) : GLP-1R sinoatrial node 2 10 GLP-1 RAs : GLP-1R paraventricular nucleus arcuate nucleus hypothalamus, nucleus tractus solitarius area postrema : GLP-1R (natriuresis) (nephroprotection) : GLP-1R Brunners glands myenteric plexus macrophages T cells GLP-1RAs (atherosclerosis): GLP-1R atherosclerotic plaques GLP-1R macrophages macrophages foam cells : nitric oxide (NO) : GLP-1RAs atherosclerotic plaques Nuclear Factor-B (NF-B): Interleukin-6 (IL_6) Tumor Necrosis Factor-alpha (TNF- ) macrophage (macrophage polarization): macrophage M1 M2 : GLP-1R (tubular cells) podocyte ferroptosis: GLP-1 RAs ferroptosis ferroptosis : GLP-1 RAs Transforming growth factor-(TGF-) : (natriuresis) (hyperfiltration) GLP-1 RAs SGLT2 inhibitors GLP-1 RAs Sodium-glucose cotransporter-2 (SGLT-2) inhibitors LEADER: liraglutide MACE ( ) 13 22 15 SUSTAIN-6: semaglutide MACE 26 39 HARMONY Outcomes: albiglutide MACE 22 6 REWIND: dulaglutide (primary prevention) 31 dulaglutide MACE 12 (4 ) FLOW trial: semaglutide semaglutide 24 (eGFR) GLP-1 RAs LEADER HbA1c (urinary albumin-creatinine ratio
